| Drug Name |
Glipizide |
| Drug ID |
BADD_D01024 |
| Description |
Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 [A179491] and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guidelines by Diabetes Canada, sulfonylurea drugs are considered a second-line glucose-lowering therapy following metformin.[L6712] Because sulfonylureas require functional pancreatic beta cells for their therapeutic effectiveness, sulfonylureas are more commonly used for early-stage type 2 diabetes when there is no progressed pancreatic failure.[T28] Compared to the first-generation sulfonylureas, such as [tolbutamide] and [chlorpropamide], second-generation sulfonylureas contain a more non-polar side chain in their chemical structure, which enhances their hypoglycemic potency.[A179488] Compared to other members of the sulfonylurea drug group, glipizide displays rapid absorption and onset of action with the shortest half-life and duration of action, reducing the risk for long-lasting hypoglycemia that is often observed with blood glucose-lowering agents.[A179485] Glipizide was first approved by the FDA in 1994 and is available in extended-release tablets under the brand name Glucotrol®, as well as in combination with metformin under the brand name Metaglip®. |
| Indications and Usage |
Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.[label] |
| Marketing Status |
approved; investigational |
| ATC Code |
A10BB07 |
| DrugBank ID |
DB01067
|
| KEGG ID |
D00335
|
| MeSH ID |
D005913
|
| PubChem ID |
3478
|
| TTD Drug ID |
D0Z4SB
|
| NDC Product Code |
12828-0051; 17373-1060; 16714-895; 51655-966; 63629-1394; 63629-2203; 67544-302; 68071-4498; 68645-574; 0591-0460; 0591-0845; 71335-1031; 0591-0461; 12780-4680; 53747-047; 62147-0400; 50090-4297; 50090-6473; 53002-4111; 55289-806; 59651-270; 59762-0540; 61919-722; 62559-315; 63187-811; 63629-2202; 67544-097; 68071-3009; 68084-111; 68382-337; 68645-575; 70518-2624; 70771-1098; 50268-362; 51407-621; 51655-180; 51655-982; 53002-1111; 58118-0141; 59651-268; 60760-568; 68071-4223; 68382-336; 70518-1124; 70771-1100; 70934-666; 71335-1042; 55700-624; 59651-780; 60687-690; 61919-287; 0049-0174; 68788-0142; 70518-1848; 70518-2573; 71205-041; 71335-0618; 70518-1063; 71335-0930; 71335-9614; 71335-9742; 71610-680; 17373-1061; 54752-0054; 16714-894; 50090-0505; 50268-361; 59762-0542; 63629-2204; 0049-0170; 64980-280; 64980-281; 67296-1267; 68788-8138; 70518-0552; 70518-3645; 70518-3688; 70934-300; 70934-862; 70934-878; 71610-668; 0615-8407; 72603-116; 17337-0230; 51927-0284; 16714-896; 16729-140; 43063-861; 50090-0502; 55154-7987; 59651-782; 60687-480; 60760-165; 63187-993; 63629-1398; 67296-2042; 68071-2839; 68788-8243; 70518-0579; 0591-0844; 72789-130; 51927-0248; 53002-4460; 59762-0541; 60505-0141; 68071-4085; 68788-0141; 68788-7856; 71610-388; 0049-1582; 59651-269; 66326-400; 16729-139; 43353-207; 43353-379; 51407-620; 53002-4462; 55700-585; 59651-781; 0049-0178; 63629-5256; 0378-1110; 64980-279; 68382-335; 68788-8487; 70771-1099; 70934-098; 0591-0900; 71610-105; 71610-175; 71610-393; 0904-6637; 0049-1581; 24196-176; 48589-0008; 49452-3299; 42708-109; 60505-0142; 60687-682; 60687-701; 60760-329; 62559-316; 63187-255; 63187-477; 0378-1105; 68084-112; 68788-8192; 70518-2888; 71335-1130; 72189-070; 0615-8408; 72603-117; 38779-0765; 58793-005; 62147-0001; 43353-369; 50090-5040; 50090-5806; 51655-983; 53002-2111; 53002-4461; 55289-301; 55289-779 |
| UNII |
X7WDT95N5C
|
| Synonyms |
Glipizide | Glypidizine | Glidiazinamide | Glydiazinamide | Glucotrol | Minidiab | Mindiab | Minodiab | K-4024 | K 4024 | K4024 | Melizide | Ozidia | Glupitel |
